1: Executive Summary
The Brain Industry Revealed Neuropharmaceuticals Cell Therapies Neurodevices Neurodiagnostics
Investment Risks and Opportunities Translating Neuroscience into Neurotech The Neurotech Market Opportunity
Key Industry Facts and Findings
2: Trends and Drivers
Converging Technology Drivers Crossing the Blood Brain Barrier Demographic Drivers More People Living Longer Social Drivers The Lifestyle Improvement Market Economic Drivers Global Economic Burden of Brain-Related Illness Rising Health Care Costs Research Funding US Government Research Funding Stem Cell Funding International Government Research Funding Foundations Focus on the Brain Intellectual Property Trends Global Intellectual Property Protection Patent Expirations
Neurotech Merger and Acquisition Activity (2005-Q12012)
3: Neuropharmaceutical Sector
Neuropharmaceutical Sector Overview Trends in Neuropharmaceuticals Big Pharma Scales Back Treatments in Development and Abandoned by Indication 2006-2012
Neuropharmaceutical Partnering and Licensing Partnering and Licensing Personnel Partnering and Licensing Deals 2004-Q12012 Neurology Markets and Pipelines Alzheimer’s Disease (AD) AAMI and MCI Epilepsy and Seizure Disorders Huntington's disease Migraine Multiple Sclerosis Parkinson’s Disease Sleep Disorders Restless Legs Syndrome Stroke Traumatic Brain Injury Psychiatry Markets and Pipelines Addiction Anxiety Disorders Attention Disorders Depressive Disorders Bipolar Disorder Obesity Schizophrenia Cognitive Impairment Associated with Schizophrenia Sensory Markets and Pipelines Pain Retinal Disorders
4: Stem Cells and Neuroregeneration
Defining Stem Cell Markets and Players Therapeutics Drug Discovery Tools Stem Cell Banking Stem Cell Approaches Background The Science of Transplantion Controlling Immune Rejection and Infection Sources and Harvesting of Stem Cells Embronic Stem Cells Fetal Stem Cells Adult Stem Cells Stimulation of Endogenous Stem Cells Stem Cells Scientific Hurdles Markets and Treatments in Development Alzheimer’s Disease Amyotrophic Lateral Sclerosis (ALS) Hearing Loss Huntington’s Disease (HD) Multiple Sclerosis (MS) Parkinson’s Disease Retinal Disorders Spinal Cord Injury (SCI) Stroke Other CNS Diseases
|
5: Neurodevice Sector
Neurodevice Sector Overview Neurodevice Markets Regulatory Process in the US Regulatory Process in the EU Neurodevice Sector Trends Investment by Major Device companies Neurodevice M&A Activity (2005-Q12012)
Neuroprosthetic Devices Cochlear Implants Retinal Implants Motor Prostheses and Brain Computer Interfaces
Neuromodulation Devices Neuromodulation Device Clinial Trials and Recent Approvals Deep Brain Stimulation Essential Tremor Parkinson’s Disease Primary Dystonia Severe Obsessive Compulsive Disorder Treatment-Resistant Depression Epilepsy Traumatic Brain Injury and Stroke Transcranial Magnetic Stimulation (TMS) Alzheimer's Treatment Resistant Depression Migraine Spinal Cord Stimulation (SCS) Chronic and Neuropathic Pain Spinal Cord Injury Vagus Nerve Stimulation (VNS) Epilepsy Treatment-Resistant Depression Obesity Peripheral Stimulation Assisted Breathing Epilepsy Fecal Incontinence Foot Drop Hypertension Migraine Neuropathic Pain Restless Legs Syndrome Sleep Apnea Stroke Urinary Conditions Gastric Modulation and Obesity
Neurosurgical devices Radiosurgical Devices Neurosurgical Navigation and Equipment Image Guided Navigation (IGN) Intraoperative Magnetic Resonance Imaging (iMRI) Automated Surgical Systems Brain Monitoring Temperature Control Systems Neurovascular Intervention Ischemic Stroke Catheters, Stents and Perfusion devices Retrieval and Protection devices Ultrasound Thrombolysis Hemorrhagic Stroke Coils Liquid Embolics Stents Neurosoftware Attention Deficit Disorder Cognition and Aging Stress and Emotional Wellbeing Autism Addiction and Obesity Pain Schizophrenia
6: Neurodiagnostics Sector
Neurodiagnostic Sector Overview FDA Approval and Reimbursement of Diagnostics Neuroimaging Technologies Computed Tomography (CT) Magnetic Resonance Imaging (MRI) Nuclear Medicine Imaging (PET, SPECT) Electro-encephalography (EEG) Magneto-encephalography (MEG) In Vitro Diagnostics In Vitro Diagnostics Regulatory Landscape Emerging Diagnostics for Alzheimer’s Disease Emerging Diagnostics for TBI Genetic Testing and Pharmacogenomics Protein Biomarker Assays Pattern Recognition in Diagnostics Emerging Diagnostics for Psychiatry Emerging Diagnostics for Autism Neuroinformatics Diagnostic Software
7: Private Neurotechnology Investment
Private Investment in Neurotechnology Venture Capital Investment Trends Neurotech Venture Capital Investment Investing in Neuropharmaceuticals Investing in Stem Cells and Neuroregeneration Investing in Neurodevices Investing in Neurodiagnostics Private Company Financings, 2011 Top financings 2004-2011 Leading Neurotech Investors Leading Venture Capital Firms
8: Public Neurotechnology Investment
Investing in Public Neurotech Companies Neurotech Stock Universe Neurotech Initial Public Offerings NASDAQ NeuroInsights Neurotech Index
9: Neurotechnology Research Centers
Leading Neurotechnology Research Centers University of California, San Francisco (UCSF) University of California, Los Angeles (UCLA) University of California, San Diego (UCSD) Harvard Stanford University Massachusetts Institute of Technology (MIT) Columbia University Washington University, St. Louis University College London (UCL) Karolinska Institutet, Stockholm RIKEN Brain Science Institute, Japan Places to Watch National Brain Research Centre (NBRC), India Neurosciences Victoria, Australia (NSV) Univeristy of Helsinki, Finland
10: Leading Neurotechnology Regions
The Global Neurotech Economy Nexus Ranking and Methodology Established Neurotech Nexus’ Emerging Neurotech Nexus’ Nascent Neurotech Nexus’ Conclusions and Policy Recommendations
11: Company Profiles
Neuropharmaceutical & Cell Therapy Companies: Private Neuropharmaceutical & Cell Therapy Companies: Public Neurodevice Companies: Private Neurodevice Companies: Public Neurodiagnostic Companies: Private Neurodiagnostic Companies: Public
12: Index
|